Document Detail


Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine.
MedLine Citation:
PMID:  20649629     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
AIM: To estimate absolute and relative incidence rates of hypoglycaemia when using once-daily evening or morning regimens of insulin glargine (glargine) versus once-daily evening NPH insulin (NPH) using individual patient data (IPD).
MATERIALS AND METHODS: Randomized controlled trials with accessible IPD and including white European people with type 2 diabetes (T2DM) using glargine or NPH once-daily (with oral glucose-lowering drugs) were identified. Two study pools were analysed: evening glargine versus evening NPH (pool 1); and morning glargine versus evening NPH (pool 2). The number-needed-to-treat to avoid hypoglycaemia was calculated for glargine versus NPH.
RESULTS: In study pool 1 (n = 2711), the risk of nocturnal hypoglycaemia was approximately halved with glargine compared with NPH [odds ratios (OR): 0.44-0.52, p < 0.001-0.047]. This led to a significant reduction in anytime risk of symptomatic hypoglycaemia [plasma glucose (PG) <3.9 mmol/l, OR: 0.64, p = 0.018; PG <2.0 mmol/l, OR: 0.51, p < 0.001]. In study pool 2 (n = 470), although a strong numerical reduction in all types of nocturnal hypoglycaemia was observed (OR: 0.16-0.64), statistical significance was reached only for symptomatic hypoglycaemia with PG <3.9 mmol/l (p < 0.001). Eight (pool 1) or five (pool 2) people with T2DM needed to use glargine rather than NPH to avoid one person from experiencing a nocturnal symptomatic hypoglycaemic event within a median of about 25 weeks of starting insulin.
CONCLUSIONS: This meta-analysis of open-label studies provides confidence that reductions of around 50% of risk for nocturnal hypoglycaemia can be achieved with using glargine instead of NPH.
Authors:
P D Home; A Fritsche; S Schinzel; M Massi-Benedetti
Related Documents :
16842479 - Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: ...
18715209 - Beyond the era of nph insulin--long-acting insulin analogs: chemistry, comparative phar...
16021649 - A randomized multicentre trial of insulin glargine compared with nph insulin in people ...
8382139 - Coagulation and fibrinolytic systems in type i diabetes: effects of venous occlusion an...
767189 - Effects of intermittent hypoglycaemia in pregnant rats on the functional development of...
8775749 - Diabetes mellitus and traffic incidents.
22278939 - Toll-like receptors 2 and 4 impair insulin-mediated brain activity by interleukin-6 and...
11803199 - A new mesangial triumvirate: sulfonylureas, their receptors and endosulfines.
274319 - Control of phosphoenolpyruvate carboxykinase in brown adipose tissue of infant rats.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  12     ISSN:  1463-1326     ISO Abbreviation:  Diabetes Obes Metab     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-07-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  England    
Other Details:
Languages:  eng     Pagination:  772-9     Citation Subset:  IM    
Affiliation:
Institute of Cellular Medicine-Diabetes, Newcastle University, Newcastle upon Tyne, UK. philip.home@newcastle.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those w...
Next Document:  Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared w...